Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06442462 · ClinicalTrials.gov registry record · Phase 2

Study of SPG302 in Adults With Schizophrenia

A Phase 2 study of Schizophrenia, sponsored by Spinogenix.

Active
Registry status
Phase 2
Development phase
32
Enrollment target
3
Study locations

NCT06442462: Active Phase 2 study of Schizophrenia, sponsored by Spinogenix.

NCT06442462 is a Phase 2 study of Schizophrenia that is active but no longer recruiting, run by Spinogenix. The registered enrollment target is 32 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06442462, a Phase 2 study of Schizophrenia, is active but no longer recruiting, sponsored by Spinogenix.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Primary Outcome

The PANSS is a scale to measure symptom severity of schizophrenia. Thirty symptoms of schizophrenia are evaluated by a clinician on a seven point sale, with 1 = absence of symptoms and 7 = extremely severe symptoms. This study will rate each score change by calculating the difference between baseline scale and completion of study intervention.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG SPG302

Study Locations (3)

Victoria

  • Box Hill Hospital - Eastern Health - Box Hill
  • Multidisciplinary Alfred Psychiatry Research Centre (MAPrc) - Melbourne

California

  • CenExel CNS - Garden Grove

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-08-01
Est. Completion 2026-03
Phase Phase 2
Spinogenix

2 total trials

What the registry record for NCT06442462 still lists

NCT06442462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06442462 reports a single indexed study location in Victoria, California.

Frequently Asked Questions

What is clinical trial NCT06442462 about?

NCT06442462 is a clinical study titled "Study of SPG302 in Adults With Schizophrenia". This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

What is the current status of trial NCT06442462?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-08-01. Estimated completion is 2026-03.

What conditions does trial NCT06442462 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT06442462?

The interventions under investigation include: Placebo (DRUG), SPG302 (DRUG).

Who is sponsoring clinical trial NCT06442462?

This trial is sponsored by Spinogenix, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06442462 being conducted?

This trial has 3 study locations across California, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06442462's enrollment target sits among peer trials

32 256th of 315 higher than 58 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06442462, the US trial registry maintained by the National Library of Medicine. NCT06442462 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.